# Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

> **NCT01048099** · NA · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 283 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** PRO Onc Assay and Treatment
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT01048099
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2016-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01048099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01048099, "Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01048099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*